{
    "clinical_study": {
        "@rank": "130987", 
        "acronym": "PREFERE", 
        "arm_group": [
            {
                "arm_group_label": "radical prostatectomy", 
                "arm_group_type": "Experimental", 
                "description": "Procedure/Surgery: radical prostatectomy"
            }, 
            {
                "arm_group_label": "percutaneous radiation therapy", 
                "arm_group_type": "Experimental", 
                "description": "Radiation: percutaneous radiation therapy"
            }, 
            {
                "arm_group_label": "permanent seed implantation", 
                "arm_group_type": "Experimental", 
                "description": "Radiation: permanent seed implantation"
            }, 
            {
                "arm_group_label": "Active Surveillance", 
                "arm_group_type": "Experimental", 
                "description": "Procedure/Surgery: Active Surveillance"
            }
        ], 
        "brief_summary": {
            "textblock": "4arms preference based Study to compare four therapy options in prostate cancer with low or\n      early intermediate risk"
        }, 
        "brief_title": "Evaluation of Four Treatment Modalities in Prostate Cancer With Low or \"Early Intermediate\" Risk", 
        "completion_date": {
            "#text": "December 2030", 
            "@type": "Anticipated"
        }, 
        "condition": "Prostate Cancer", 
        "condition_browse": {
            "mesh_term": "Prostatic Neoplasms"
        }, 
        "detailed_description": {
            "textblock": "The study will compare four possible therapy options for treatment of newly diagnosed\n      prostate cancer with low or \"early intermediate\" risk according to the patients preferences.\n\n      The Following hypotheses will be tested:\n\n        -  Radiation is not relevantly worse compared to prostatectomy with regard to time to\n           prostate cancer-related deaths\n\n        -  Permanent seed implantation therapy not inferior to prostatectomy with regard to time\n           to prostate cancer-related deaths.\n\n        -  Active Surveillance does not lead to a significant decrease of time to prostate\n           cancer-related deaths compared to prostatectomy.\n\n      That for patients with newly diagnosed prostate cancer will be randomized into one of the\n      four treatment arms. Randomization may be limited to at least two of the four treatment arms\n      if a patient refuses one or two of the four treatment arms according to his own preference."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Newly diagnosed, biopsy proven adenocarcinoma of the prostate (ultrasound guided\n             biopsy by standardized protocol)\n\n          -  Men aged 18-75 years\n\n          -  Recruitment within 3 months after histological confirmation\n\n          -  Localized prostata cancer <= cT2a, NX or N0 M0\n\n          -  PSA <= 10 ng / ml\n\n          -  Gleason score <= 7a (3 +4)\n\n          -  ECOG performance status 0 or 1\n\n          -  <= 30% positive biopsy cores with largest contiguous tumor length <= 5 mm\n\n          -  IPSS score < 18\n\n          -  Urine flow (Qmax):> 15 ml / s\n\n        Exclusion Criteria:\n\n          -  Unifocal Gleason 6 cancer <1mm\n\n          -  History of treatment for BPH e.g. TURP, HIFU or cryotherapy\n\n          -  History of radiation therapy to the pelvis\n\n          -  Life expectancy <10 years\n\n          -  ASA >= 4\n\n          -  Post-void residual urine > 50 ml\n\n          -  Prostate volume on transrectal ultrasound > 60 cm3\n\n          -  large median prostate lobe visualized on transrectal ultrasound\n\n          -  chronic intestinal inflammatory disease covering the rectum\n\n          -  Other active malignancy within the past 5 years (except for superficial basal cell\n             carcinoma or non muscle infiltrating bladder carcinoma)\n\n          -  contraindications for prostatectomy, radiation therapy or Active Surveillance\n\n          -  Patients refusing written informed consent"
            }, 
            "gender": "Male", 
            "healthy_volunteers": "No", 
            "maximum_age": "75 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "7600", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 26, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01717677", 
            "org_study_id": "AP 65/11", 
            "secondary_id": "DRKS00004405"
        }, 
        "intervention": [
            {
                "arm_group_label": "radical prostatectomy", 
                "intervention_name": "radical prostatectomy", 
                "intervention_type": "Procedure"
            }, 
            {
                "arm_group_label": "percutaneous radiation therapy", 
                "intervention_name": "percutaneous radiation therapy", 
                "intervention_type": "Radiation"
            }, 
            {
                "arm_group_label": "permanent seed implantation", 
                "intervention_name": "permanent seed implantation", 
                "intervention_type": "Radiation"
            }, 
            {
                "arm_group_label": "Active Surveillance", 
                "intervention_name": "Active Surveillance", 
                "intervention_type": "Procedure"
            }
        ], 
        "is_fda_regulated": "No", 
        "lastchanged_date": "June 11, 2013", 
        "location": [
            {
                "contact": {
                    "email": "thomas.wiegel@uniklinik-ulm.de", 
                    "last_name": "Thomas Wiegel, Prof. Dr.", 
                    "phone": "0731-50056101"
                }, 
                "facility": {
                    "address": {
                        "city": "Ulm", 
                        "country": "Germany", 
                        "state": "Albert-Einstein-Allee 23", 
                        "zip": "89081"
                    }, 
                    "name": "Universit\u00e4tsklinikum"
                }, 
                "investigator": {
                    "last_name": "Thomas Wiegel, Prof. Dr.", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "michael.stoeckle@uks.eu", 
                    "last_name": "Michael St\u00f6ckle, Prof. Dr.", 
                    "phone": "06841/162-47 02"
                }, 
                "facility": {
                    "address": {
                        "city": "Homburg/Saar", 
                        "country": "Germany", 
                        "state": "Kirrberger Stra\u00dfe", 
                        "zip": "66424"
                    }, 
                    "name": "Universit\u00e4tsklinikum"
                }, 
                "investigator": {
                    "last_name": "Michael St\u00f6ckle, Prof. Dr.", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "Germany"
        }, 
        "number_of_arms": "4", 
        "official_title": "Preference Based Randomized Trial for Evaluation of Four Treatment Modalities in Prostate Cancer With Low or \"Early Intermediate\" Risk", 
        "overall_contact": {
            "email": "studienzentrale@prefere.de", 
            "last_name": "Roswitha Bussar-Maatz", 
            "phone": "(0)30 322 932 946"
        }, 
        "overall_official": [
            {
                "affiliation": "Klinik f\u00fcr Urologie und Kinderurologie der Universit\u00e4t des Saarlandes", 
                "last_name": "Michael St\u00f6ckle, Prof. Dr.", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Klinik f\u00fcr Strahlentherapie und Radioonkologie der Universit\u00e4t Ulm", 
                "last_name": "Thomas Wiegel, Prof. Dr.", 
                "role": "Principal Investigator"
            }
        ], 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Germany: Federal Institute for Drugs and Medical Devices", 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "December 2029", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Prostate cancer-specific survival", 
            "safety_issue": "No", 
            "time_frame": "minimal observation time of 13 years for last study patient"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01717677"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "- Overall survival", 
                "safety_issue": "No", 
                "time_frame": "minimal observation time of 13 years for last study patient"
            }, 
            {
                "measure": "- Time to onset of hormone therapy", 
                "safety_issue": "No", 
                "time_frame": "17 years"
            }, 
            {
                "measure": "- Occurrence of the first progression on hormone therapy", 
                "safety_issue": "No", 
                "time_frame": "17 years"
            }, 
            {
                "measure": "- Quality of life on EORTC-QLQ-C30 with additional modul PCA (EORTCQLQ- PR25) as well as HADS-D at baseline", 
                "safety_issue": "No", 
                "time_frame": "before and 3 Mon. after therapy as well as after 1, 2, 3, 5, 7, 10 and 13 years"
            }, 
            {
                "measure": "- Complications / Safety", 
                "safety_issue": "Yes", 
                "time_frame": "median 15 years"
            }
        ], 
        "source": "Association of Urogenital Oncology (AUO)", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Association of Urogenital Oncology (AUO)", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "October 2012", 
        "study_design": "Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "November 2012"
    }
}